Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 2/20 | 0.34 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 5/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 5/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17545524 | 0.96 | ALDH1A1 (0.39) | L3MBTL3CNR2ALDH1A1L3MBTL1DRD2 | |
| SCHEMBL16432708 | 0.86 | PIK3C3 (0.33) | PIK3C3CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL29605672 | 0.86 | PIK3C3 (0.33) | PIK3C3CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL18818520 | 0.84 | L3MBTL3 (0.40) | L3MBTL3ALDH1A1L3MBTL1CHRNB4CHRNA3 | |
| SCHEMBL12946007 | 0.84 | L3MBTL3 (0.40) | L3MBTL3DRD2CHRNB4CHRNA3CHRNB2 | |
| SCHEMBL3022699 | 0.80 | PIK3C3 (0.36) | CNR2ALDH1A1L3MBTL1PIK3C3CHRNB4 | |
| SCHEMBL15849329 | 0.79 | L3MBTL3 (0.35) | L3MBTL3 | |
| SCHEMBL17540086 | 0.77 | PIK3C3 (0.32) | PIK3C3 | |
| SCHEMBL19275744 | 0.77 | PIK3C3 (0.36) | PIK3C3CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL19574059 | 0.76 | CHRNB4 (0.36) | CNR2ALDH1A1L3MBTL1CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9556191-B2 | Aminoquinazoline derivatives and their salts and methods of use thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-01-31 | — | — | US | disclosed |
| US-20160039838-A1 | AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-02-11 | — | — | US | disclosed |
| WO-2014177038-A1 | AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2014-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039838-A1 | AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE THEREOF | WNK1, ABL1, NEK4 | L3MBTL3 4054/4885CNR2 2300/4885ALDH1A1 3364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.